LIVIVO - Search results -

Search results

Result 1 - 10 of total 1564

Search options

Article: [Overview of systematic reviews of Shufeng Jiedu Capsules].

Xu, Guo-Qiang / Zhao, Qi-Liang / Wang, Xiao-Yu / Zhang, Dong / Fan, Shuang / Zhang, Hui-Qi / Wang, Mu-Tian / Chen, Ming-Hu / Liu, Min

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

2022 Volume 47, Issue 4, Page(s) 1103–1113

Abstract: ... the good clinical efficacy of Shufeng Jiedu Capsules in the treatment of respiratory diseases ... Meta-analysis of Shufeng Jiedu Capsules to provide evidence support for clinical practice. The systematic ... reviews/Meta-analysis of Shufeng Jiedu Capsules were searched from CBM, Wanfang, CNKI, VIP, PubMed, EMbase ...

Abstract	At present, there have been many clinical trials and systematic reviews/Meta-analysis proving the good clinical efficacy of Shufeng Jiedu Capsules in the treatment of respiratory diseases, while comprehensive discussion is still required. This article overviews and analyzes the systematic reviews/Meta-analysis of Shufeng Jiedu Capsules to provide evidence support for clinical practice. The systematic reviews/Meta-analysis of Shufeng Jiedu Capsules were searched from CBM, Wanfang, CNKI, VIP, PubMed, EMbase and Cochrane Library. The AMSTAR 2 scale and GRADE system were respectively employed for the evaluation of methodological quality and the grading of evidence quality. Finally, 8 systematic reviews/Meta-analysis published during 2018-2021 were included for analysis. The diseases involved include acute exacerbation of chronic obstructive pulmonary disease, community-acquired pneumonia, acute tonsillitis, acute exacerbation of chronic bronchitis and acute upper respiratory tract infection. The number of included RCTs studies ranged from 8 to 25. The results showed that Shufeng Jiedu Capsules combined with western medicine routine had better therapeutic effect than the latter alone in the treatment of the above five diseases. The reported adverse reactions caused by Shufeng Jiedu Capsules were mainly gastrointestinal discomforts such as mild nausea, diarrhoea and vomiting, with low incidence and mild symptoms, which can be relieved by drug withdrawal. The methodological quality of the included studies was extremely low, and the outcome indicators were mainly of low and very low grades. The efficacy and safety of Shufeng Jiedu Capsules in the clinical treatment of diseases still need to be verified based on more high-quality studies. The relevant clinical research and systematic review/Meta-analysis should pay more attention to methodological quality and reporting standards and strengthen the scientificity of research.
MeSH term(s)	Capsules ; Drugs, Chinese Herbal/therapeutic use ; Systematic Reviews as Topic ; Treatment Outcome
Chemical Substances	Capsules ; Drugs, Chinese Herbal ; shufeng jiedu
Language	Chinese
Publishing date	2022-03-13
Publishing country	China
Document type	Journal Article ; Review
ZDB-ID	1004649-5
ISSN	1001-5302 ; 0254-0029
ISSN	1001-5302 ; 0254-0029
DOI	10.19540/j.cnki.cjcmm.20210712.501
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3056: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection.

Han, Yanqi / Xu, Jun / Zhu, Qiang / Yang, Li / Wang, Yitao / Luo, Hua / Zhang, Tiejun

Chinese medicine

2023 Volume 18, Issue 1, Page(s) 45

Abstract: Shufeng Jiedu Capsule (SFJDC), composed of eight herbs, is a big brand traditional Chinese medicine ...

Abstract	Shufeng Jiedu Capsule (SFJDC), composed of eight herbs, is a big brand traditional Chinese medicine (TCM) for the treatment of different respiratory tract infectious diseases with good clinical efficacy and few side effects. It is clinically applied to acute upper respiratory tract infection(URI), influenza, acute exacerbation of chronic obstructive pulmonary disease (AECOPD), community-acquired pneumonia(CAP) and other diseases, due to its antibacterial, antiviral, anti-inflammatory, immunoregulatory and antipyretic activities. In particular, it has shown good clinical effects for COVID-19, and was included in the fourth to tenth editions of the 'Diagnosis and Treatment Protocol for COVID-19 (Trial)' by the National Health Commission. In recent years, studies on the secondary development which focus on the basic and clinical application of SFJDC have been widely reported. In this paper, chemical components, pharmacodynamic material basis, mechanisms, compatibility rule and clinical application were systematically summarized, in order to provide theoretical and experimental basis for further research and clinical application of SFJDC.
Language	English
Publishing date	2023-04-25
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2260322-0
ISSN	1749-8546
ISSN	1749-8546
DOI	10.1186/s13020-023-00749-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis.

Sheng, Xiaodi / Chen, Chao / Jiang, Guowang / Ji, Zhaochen / Guo, Zehui / Hu, Haiyin / Wang, Hui / Zhai, Jingbo / Zhang, Dong / Zhang, Junhua / Guo, Liping

Frontiers in medicine

2022 Volume 9, Page(s) 1020286

Abstract: Introduction: Shufeng Jiedu capsule (SFJD) is a commonly used Chinese patent medicine in China ...

Abstract	Introduction: Shufeng Jiedu capsule (SFJD) is a commonly used Chinese patent medicine in China. Some studies have reported that SFJD has therapeutic effects in patients diagnosed with COVID-19. This systematic review aimed to critically evaluate the efficacy and safety of SFJD combined with western medicine (WM) for treating COVID-19. Methods: A literature search by using WHO COVID-19 database, PubMed, Embase, Cochrane Library, the Web of Science, CKNI, Wanfang, VIP, SinoMed, and clinical trial registries was conducted, up to 1 August 2022. Randomized controlled trials (RCTs), non-RCTs, cohort studies and case series of SFJD combined with WM for COVID-19 were included. Literature screening, data extraction, and quality assessment were performed independently by two reviewers in line with the same criteria. We used the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) to assess the certainty of evidence. Meta-analyses were performed with Revman 5.3 if possible. The descriptive analysis was conducted when the studies could not be meta-analyzed. Results: Totally 10 studies with 1,083 patients were included. Their methodological quality were moderate. The results demonstrated that compared to WM group, SFJD + WM group remarkably increased the nucleic acid negative conversion rate ( Conclusion: SFJD combined with WM seems more effective than WM alone for the treatment of COVID-19. However, more well-designed RCTs still are warranted. Systematic review registration: [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022306307].
Language	English
Publishing date	2022-10-13
Publishing country	Switzerland
Document type	Systematic Review
ZDB-ID	2775999-4
ISSN	2296-858X
ISSN	2296-858X
DOI	10.3389/fmed.2022.1020286
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: A synthesis of the evidence regarding safety of a Chinese herbal formula Shufeng Jiedu

Jeanne Trill / Zhijie Wang / Merlin Willcox / Yu Zhang / Xiao-Yang Hu / Michael Moore

Pharmacological Research - Modern Chinese Medicine, Vol 2, Iss , Pp 100017- (2022)

A pharmacological review

2022

Abstract: Shufeng Jiedu capsule (SFJDC) is a Chinese herbal medicine formula for treating acute ...

Abstract	Shufeng Jiedu capsule (SFJDC) is a Chinese herbal medicine formula for treating acute respiratory tract infections. This review aims to assess its potential safety for clinical setting.Systematic literature searches were conducted across multiple databases to: investigate the phytochemistry and safety data on SFJD and its constituents; and to produce a meta-analysis of RCTs reporting safety concerns (all ages) receiving SFJDC capsule (any condition). The primary outcome was the incidence of adverse events (AEs) or complications associated with taking SFJDC with/without usual care compared with placebo or usual care.Pharmacovigilance data reporting AEs to the Chinese National Adverse Drug Reaction Monitoring System in 2017/2018 was analysed.Safety information was insufficient regarding pregnancy/lactation (all herbs). Laboratory studies raised theoretical concerns regarding saikosaponins A and D elevating blood glucose; glycyrrhizin inducing hypertension and hypokalaemia; and saikosaponins/resveratrol/lignans reducing platelet activity. However, these occurred at much higher doses than used clinically.Sixty-four RCTs (7612 participants) met the meta-analysis criteria. Fourteen additional trials and two case studies were also considered. Minor AEs included nausea/vomiting, diarrhoea, unspecified gastrointestinal discomfort, dizziness and rash; these were not significantly different (statistically) to control groups.Across 2017 and 2018 sales of SFJDC packs (content 36 capsules) totalled 23.2 million. AEs recorded were 169 (2017) and 198 (2018). The majority were gastrointestinal, and improved on stopping SFJDC. None included the potential phytochemical concerns (regarding platelets, hypertension, hypokalaemia, blood glucose).No serious AEs were identified from the included trials or pharmacovigilance data.No substantive safety concerns were identified for SFJD for clinical use; excluding pregnant/lactating women.
Keywords	Herbal medicine ; Shufeng Jiedu ; Safety ; Side effect ; Adverse event ; Meta-analysis ; Other systems of medicine ; RZ201-999 ; Therapeutics. Pharmacology ; RM1-950
Subject code	610
Language	English
Publishing date	2022-03-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection

Yanqi Han / Jun Xu / Qiang Zhu / Li Yang / Yitao Wang / Hua Luo / Tiejun Zhang

Chinese Medicine, Vol 18, Iss 1, Pp 1-

2023 Volume 11

Abstract: Abstract Shufeng Jiedu Capsule (SFJDC), composed of eight herbs, is a big brand ...

Abstract	Abstract Shufeng Jiedu Capsule (SFJDC), composed of eight herbs, is a big brand traditional Chinese medicine (TCM) for the treatment of different respiratory tract infectious diseases with good clinical efficacy and few side effects. It is clinically applied to acute upper respiratory tract infection(URI), influenza, acute exacerbation of chronic obstructive pulmonary disease (AECOPD), community-acquired pneumonia(CAP) and other diseases, due to its antibacterial, antiviral, anti-inflammatory, immunoregulatory and antipyretic activities. In particular, it has shown good clinical effects for COVID-19, and was included in the fourth to tenth editions of the ‘Diagnosis and Treatment Protocol for COVID-19 (Trial)’ by the National Health Commission. In recent years, studies on the secondary development which focus on the basic and clinical application of SFJDC have been widely reported. In this paper, chemical components, pharmacodynamic material basis, mechanisms, compatibility rule and clinical application were systematically summarized, in order to provide theoretical and experimental basis for further research and clinical application of SFJDC.
Keywords	Big brand traditional Chinese medicine ; Shufeng Jiedu Capsule ; Secondary development of TCM ; Respiratory tract infections ; Systematical research ; Other systems of medicine ; RZ201-999
Subject code	610
Language	English
Publishing date	2023-04-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Potential therapeutic effect of Shufeng Jiedu capsule and its major herbs on coronavirus disease 2019 (COVID-19): A review.

Xu, Yayun / Yang, Li / Wang, Longfei / Chen, Feihu

Drug discoveries & therapeutics

2021 Volume 15, Issue 6, Page(s) 289–299

Abstract: ... to human health and social stability. Shufeng Jiedu capsule (SFJDC), a patented herbal drug composed of eight ...

Abstract	The outbreak and rapid spread of coronavirus disease 2019 (COVID-19) poses a huge threat to human health and social stability. Shufeng Jiedu capsule (SFJDC), a patented herbal drug composed of eight medicinal plants, is used to treat different viral respiratory tract infectious diseases. Based on its antiviral, anti-inflammatory, and immunoregulatory activities in acute lung injury, SFJDC can be effectively used as a treatment for COVID-19 patients according to the diagnosis and treatment plan issued in China and existing clinical data. SFJDC has been recommended in 15 therapeutic regimens for COVID-19 in China. This review summarizes current data on the ingredients, chemical composition, pharmacological properties, clinical efficacy, and potential therapeutic effect of SFJDC on COVID-19, to provide a theoretical basis for its anti-viral mechanism and the clinical treatment of COVID-19.
MeSH term(s)	Anti-Inflammatory Agents ; Antiviral Agents/therapeutic use ; COVID-19 ; Drugs, Chinese Herbal/therapeutic use ; Humans ; SARS-CoV-2
Chemical Substances	Anti-Inflammatory Agents ; Antiviral Agents ; Drugs, Chinese Herbal ; shufeng jiedu
Language	English
Publishing date	2021-12-30
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	2568828-5
ISSN	1881-784X ; 1881-784X
ISSN (online)	1881-784X
ISSN	1881-784X
DOI	10.5582/ddt.2021.01099
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: [Effect of influenza virus on chemokine pathways in mice lungs and intervention of Shufeng Xuanfei Jiedu formula].

Liu, Qi / Wang, Jianguo / Li, Baozhen / Jia, Lu / Guo, Yu / Yang, Wanfang

Zhonghua wei zhong bing ji jiu yi xue

2021 Volume 33, Issue 4, Page(s) 405–409

Abstract: ... to explore the intervention effect of Shufeng Xuanfei Jiedu formula.: Methods: Male ICR mice were divided ... group) and Shufeng Xuanfei Jiedu formula high, medium and low dose groups (SH, SM, SL groups) according ... In SH, SM and SL groups, Shufeng Xuanfei Jiedu formula was used 2 hours after intranasal infection (2 ...

Abstract	Objective: To screen the differentially expressed genes on whole expression profiles of the inflammation-related cytokines in mice infected with influenza virus by the gene chip technology, and to explore the intervention effect of Shufeng Xuanfei Jiedu formula. Methods: Male ICR mice were divided into normal group (N group), influenza virus infective model group (M group), Oseltamivir control group (C group) and Shufeng Xuanfei Jiedu formula high, medium and low dose groups (SH, SM, SL groups) according to the random number table method, with 10 rats in each group. A mouse model of influenza virus pneumonia was reproduced by nasal drip of influenza virus strain FM1 (0.05 mL). In N group, 0.05 mL normal saline was used. In SH, SM and SL groups, Shufeng Xuanfei Jiedu formula was used 2 hours after intranasal infection (2 times, equal and 1/2 of the clinical treatment dose, approximately 3.8, 1.9 and 1.0 g×mL Results: Compared with the N group, the lung index in the M group was significantly higher, and pathological changes were found in lung tissue, which suggested that the model of influenza virus infection was successfully established. Compared with the M group, the lung index of mice in C, SH, SM, SL groups was significantly lower (0.96±0.14, 1.45±0.22, 1.14±0.18, 1.22±0.21 vs. 1.72±0.15, all P < 0.05), and the extent and degree of lesions were reduced, however, there was no significant difference among the groups. Gene chip analysis showed that there were more differentially expressed genes in N group vs. M group, SH group vs. M group, SM group vs. M group, SL group vs. M group. It could be used for further signal transduction pathway screening. Compared with N group, the differential gene expression of chemokine C-C ligands (CCL-3, CCL-5) and chemokine C-X-C ligands (CXCL-9, CXCL-10) in M group were significantly up-regulated [log Conclusions: Shufeng Xuanfei Jiedu formula inhibits inflammatory damage in mice after influenza virus infection by down-regulating the expressions of CCL-3, CCL-5, CXCL-9 and CXCL-10 on chemokine pathways.
MeSH term(s)	Animals ; Chemokines ; Lung ; Male ; Mice ; Mice, Inbred ICR ; Orthomyxoviridae ; Orthomyxoviridae Infections/drug therapy ; Rats
Chemical Substances	Chemokines
Language	Chinese
Publishing date	2021-05-30
Publishing country	China
Document type	Journal Article
ISSN	2095-4352
ISSN	2095-4352
DOI	10.3760/cma.j.cn121430-20201231-00782
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Shufeng Jiedu capsule inhibits inflammation and apoptosis by activating A2AAR and inhibiting NF-κB to alleviate LPS-induced ALI.

Cai, Junnan / Wang, Yu-Lian / Sheng, Xiao-Dong / Zhang, Lei / Lv, Xiongwen

Journal of ethnopharmacology

2022 Volume 298, Page(s) 115661

Abstract: Ethnopharmacological relevance: Shufeng Jiedu capsule (SFJDC) is a pure form ...

Abstract	Ethnopharmacological relevance: Shufeng Jiedu capsule (SFJDC) is a pure form of traditional Chinese medicine (TCM) that contains eight medicinal plants. Known for its anti-inflammatory and antipyretic effects, it is mostly used to treat upper respiratory tract infections and other infectious diseases, such as colds, pharyngitis, laryngitis, and tonsillitis. Both acute lung injury (ALI) and COVID-19 are closely related to lung damage, primarily manifesting as lung inflammation and epithelial cell damage. However, whether SFJDC can improve ALI and by what mechanism remain unclear. The purpose of this study was to explore whether SFJDC could be used as a prophylactic treatment for COVID-19 by improving acute lung injury. Aim of the study: The purpose of this study was to determine whether SFJDC could protect against ALI caused by lipopolysaccharide (LPS), and we wanted to determine how SFJDC reduces inflammation and apoptosis pharmacologically and molecularly. Materials and methods: Preadministering SFJDC at 0.1 g/kg, 0.3 g/kg, or 0.5 g/kg for one week was followed by 5 mg/kg LPS to induce ALI in mice. Observations included the study of lung histomorphology, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) secretion, as well as the ratio of lung wet/dry weights. In addition, RAW264.7 cells were treated for 24 h with 1 μg/mL LPS after being pretreated for 1 h with 0.5 mg/mL SFJDC. In the samples, we detected TNF-α, IL-1β, and IL-6. Cell apoptosis was detected by stimulating A549 cells for 24 h with RAW264.7 supernatant. Both in vitro and in vivo, the levels of A2A adenosine receptor (A2AAR), PKA, IκB, p-IκB, NF-κB P65 (P65), p-NF-κB P65 (p-P65), cleaved caspases-3 (Cc3), Bcl-2 associated X protein (Bax), and B-cell lymphoma-2 (Bcl-2) proteins were determined using Western blot analysis. Results: Lung tissue morphology was improved as SFJDC decreased cytokine secretion, the ratio of lung wet/dry weights, and lung tissue secretion of proinflammatory cytokines. The expression of A2AAR was increased by SFJDC, and the phosphorylation of NF-κB was inhibited. TUNEL staining and flow cytometry showed that SFJDC inhibited apoptosis by reducing the expression of Cc3 and the ratio of Bax/Bcl-2. Conclusions: According to the results of this study, SFJDC can reduce inflammation and inhibit apoptosis. A2AAR activation and regulation of NF-κB expression are thought to make SFJDC anti-inflammatory and anti-apoptotic. A wide range of active ingredients may result in an anti-inflammatory and antipyretic effect with SFJDC.
MeSH term(s)	Acute Lung Injury/chemically induced ; Acute Lung Injury/drug therapy ; Acute Lung Injury/metabolism ; Animals ; Anti-Inflammatory Agents ; Apoptosis ; COVID-19 ; Drugs, Chinese Herbal ; Inflammation/pathology ; Interleukin-6/metabolism ; Lipopolysaccharides/metabolism ; Lipopolysaccharides/toxicity ; Lung ; Mice ; NF-kappa B/metabolism ; Receptors, Purinergic P1/metabolism ; Receptors, Purinergic P1/therapeutic use ; Signal Transduction ; Tumor Necrosis Factor-alpha/metabolism ; bcl-2-Associated X Protein/metabolism
Chemical Substances	Anti-Inflammatory Agents ; Drugs, Chinese Herbal ; Interleukin-6 ; Lipopolysaccharides ; NF-kappa B ; Receptors, Purinergic P1 ; Tumor Necrosis Factor-alpha ; bcl-2-Associated X Protein ; shufeng jiedu
Language	English
Publishing date	2022-08-21
Publishing country	Ireland
Document type	Journal Article
ZDB-ID	134511-4
ISSN	1872-7573 ; 0378-8741
ISSN (online)	1872-7573
ISSN	0378-8741
DOI	10.1016/j.jep.2022.115661
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1494: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.

Ren, Huijun / Jiang, Yuhao / Wang, Shiyu / Wang, Yirong / Wang, Jingying

Medicine

2021 Volume 100, Issue 1, Page(s) e24198

Abstract: ... of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease ... AECOPD).: Methods: According to the search strategy, randomized controlled trials (RCTs) of Shufeng ... The purpose of this study was to evaluate the efficacy and safety of Shufeng Jiedu Capsule in the treatment ...

Abstract	Background: With the outbreak of novel coronavirus, the treatment of respiratory diseases has been promoted. In particular, many traditional Chinese medicines, including Chinese patent medicines, have been found to be effective in the treatment of respiratory illness in China. chronic obstructive pulmonary disease (COPD) is one of most common respiratory condition. It is predicted that COPD will be become the third frequent cause of death by 2030. The aim of this study is to assess the efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Methods: According to the search strategy, randomized controlled trials (RCTs) of Shufeng Jiedu Capsule in the treatment of AECOPD were obtained from Cochrane Library, MEDLINE, Embase, CNKI, VIP, CBM, and WANGFANG. Studies were screened according to inclusion and exclusion criteria, and the Cochrane risk bias assessment tool was used to assess the quality of the study. Meta-analysis was performed using Revman 5.4 software. Finally, the evidence level of the results will be evaluated. Results: The purpose of this study was to evaluate the efficacy and safety of Shufeng Jiedu Capsule in the treatment of AECOPD, and to provide basis for clinical rational drug use. Conclusion: Our research results of this study could provide reference for clinical decision-making and guiding development in the future COPD patient. Inplasy registration number: INPLASY2020120062.
MeSH term(s)	Capsules ; Drugs, Chinese Herbal/therapeutic use ; Humans ; Meta-Analysis as Topic ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Research Design ; Systematic Reviews as Topic
Chemical Substances	Capsules ; Drugs, Chinese Herbal ; shufeng jiedu
Language	English
Publishing date	2021-02-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	80184-7
ISSN	1536-5964 ; 0025-7974
ISSN (online)	1536-5964
ISSN	0025-7974
DOI	10.1097/MD.0000000000024198
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Effects of Shufeng Xuanfei Jiedu formula for the inflammation-related cytokines in pneumonia mice infected with influenza virus].

Liu, Qi / Wang, Jianguo / Guo, Yu / Jia, Lu / Yuan, Haijun / Yang, Wanfang / Wen, Yangxuan

Zhonghua wei zhong bing ji jiu yi xue

2020 Volume 32, Issue 2, Page(s) 183–187

Abstract: Objective: To analyze the differential gene expression of Shufeng Xuanfei Jiedu formula on whole ... pneumonia model group (M group), oseltamivir control group (C group) and Shufeng Xuanfei Jiedu formula high ... strain FM1 (0.05 mL); in group N, 0.05 mL normal saline was used. In SH, SM and SL groups, Shufeng ...

Abstract	Objective: To analyze the differential gene expression of Shufeng Xuanfei Jiedu formula on whole expression profiles of the inflammation-related cytokines in mice infected with influenza virus by the gene chip technology. Methods: Male ICR mice were divided into normal group (N group), influenza virus pneumonia model group (M group), oseltamivir control group (C group) and Shufeng Xuanfei Jiedu formula high, medium and low dose groups (SH, SM, SL groups) according to the random number table method, with 10 mice in each group. A mouse model of influenza virus pneumonia was established by nasal drip of influenza virus strain FM1 (0.05 mL); in group N, 0.05 mL normal saline was used. In SH, SM and SL groups, Shufeng Xuanfei Jiedu formula was prescribed after 2 hours of intranasal infection (drug concentration approximately 3.8, 1.9 and 1.0 kg/L), 0.2 mL once a day for 4 days; in group C, the dosage of oseltamivir was 2.5 kg/L; in group N and group M, distilled water was given. On the 5th day, the whole lung of mice was harvested, and the total RNA of lung tissue was extracted and detected after hybridization with mice whole gene expression spectrum chip. Differential expressed genes of cytokines involved in inflammatory pathways were selected. The intensity expression ratio of the chip probe signal in each group vs. M group was calculated, and P < 0.05 and log2 ratio > 1 were defined as up-regulated genes, while P < 0.05 and log2 ratio < -1 were down-regulated genes. The mRNA expressions of interleukin (IL-1, IL-8) and intercellular adhesion molecule-1 (ICAM-1) were detected by reverse transcription-polymerase chain reaction (RT-PCR). Results: Compared with group N, the differential gene expressions of IL-1, IL-8 and ICAM-1 in group M were significantly up-regulated [log2 Conclusions: Shufeng Xuanfei Jiedu formula inhibits inflammatory damage in mice after influenza virus infection by down-regulating the expressions of IL-1, IL-8, and ICAM-1 inflammatory cytokine-related genes.
MeSH term(s)	Animals ; Cytokines ; Inflammation ; Male ; Mice ; Mice, Inbred ICR ; Orthomyxoviridae ; Pneumonia ; Tumor Necrosis Factor-alpha
Chemical Substances	Cytokines ; Tumor Necrosis Factor-alpha
Language	Chinese
Publishing date	2020-04-10
Publishing country	China
Document type	Journal Article
ISSN	2095-4352
ISSN	2095-4352
DOI	10.3760/cma.j.cn121430-20190603-00034
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED